Rajesh Khanna, PhD MSc

Professor, Departments of Pharmacology, Anesthesiology, and Neuroscience 
 
Additional Contact Info: 
 Fax: 520-626-2204
 
Education: 
BSc, Toxicology, The University of Toronto, Toronto, Ontario, Canada
1990-1994
MSc, Pharmacology, The University of Toronto, Toronto, Ontario, Canada
1990-1994  Advisor: Dr. Patricia Harper
Dissertation Title: Constitutive embryonic and fetal expression of xenobiotic-metabolizing cytochrome P450s: CYP1A1, CYP1A2, and CYP1B1
PhD, Physiology, The University of Toronto, Toronto, Ontario, Canada
1997-2002 Advisor: Lyanne C. Schlichter
Dissertation Title: Expression, roles and regulation of potassium channels in neuroimmune cells
Post-doctoral fellowship, Physiology and Cellular and Molecular Neuroscience, University of California at Los Angeles, Los Angeles, California
2000-2003  Advisor: Diane M. Papazian
 
Honors and Awards: 
1990-1994 Metropolitan Life Merit Undergraduate Scholarship
Sep. 1999 American Physiological Society Travel Award
Feb., 2000 Biophysical Society Travel Award
Mar., 2000 Keystone Conference Scholarship
2001 Governor General’s Gold Medal nominee (for outstanding doctoral dissertation)
2000-2002 Natural Sciences and Engineering Research Council of Canada Postdoctoral Fellowship
2001-2003 American Heart Association Postdoctoral Fellowship
2003-2004 American Heart Association Postdoctoral Fellowship (competitive renewal)
2010 Elwert Award in Medicine, Indiana University
2011- Editor, Translational Neuroscience
2011- Scientific co-founder, Sophia Therapeutics, LLC
2012- Editorial Board Member, Journal of Pathobiology and Toxicology
2012- Editorial Board Member, the International Scholarly Research Network (ISRN)
2013 Scientific co-founder, Gabriel Therapeutics, LLC
2015 United States Patent 9,018,1732003
2015- Review Editor, Frontiers in Cellular Biochemistry
2015- Review Editor, Frontiers in Cellular Neuroscience
2015- Scientific co-founder, Regulonix, LLC
 
Major Areas of Research Interest: 
Regulation of Trafficking and Functions of Voltage-Gated Sodium and Calcium Channels; Identification of Novel Protein Regulators of Ion channels; Approaches to Targeting the Ion Channel Complexes in Neuropathic Pain and Neurodegenerative Diseases; Discovery of Novel Biologics and Small Molecules Targeting Pain and Neurodegenerative Diseases
 
Research Activities: 
The focus of my laboratory’s’ research is to understand how ion channels, specifically, voltage-gated calcium and sodium channels, are regulated by novel protein interactions. Recent studies in my laboratory have focused on targeting protein-protein interactions with biologics (peptide aptamers) and small molecules; testing the activity of these novel chemical entities in biochemical and immunofluorescent-based assays of trafficking; examining their protein interaction signatures; testing them with whole cell voltage-clamp electrophysiology and voltage- and calcium sensitive fluorescence-based imaging. Regulating these protein networks to modulate the activity of ion channels in neurodegenerative diseases (Chronic Pain, Migraine, and Neurofibromatosis) is a key focus of the laboratory. 
 
Selected Publications: 

François-Moutal L, Wang Y, Moutal A, Cottier KE, Melemedjian OK, Yang X, Wang Y, Ju W, Largent-Milnes TM, Khanna M, Vanderah TW, Khanna R#. A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory, post-operative and nerve-injury associated neuropathic pain behaviors. Pain 156(7):1247-64. PMID: 25782368.
Selected for cover image of issue

Torregrosa R, Yang XF, Dustrude ET, Cummins TR, Khanna R#, Kohn H#. Chimeric derivatives of functionalized amino acids and α-aminoamides: Compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels. Bioorg Med Chem. 2015 23(13):3655-66. PMID: 25922183.

Moutal A, Honnorat J, Massoma P, Désormeaux P, Bertrand C, Malleval C, Watrin C, Chounlamountri N, Mayeur ME, Besançon R, Naudet N, Magadoux L, Khanna R, Ducray F, Meyronet D, Thomasset N.. CRMP5 controls glioblastoma cell proliferation and survival through Notch-dependent signaling. Cancer Res. Sep 1;75(17):3519-28. PMID: 26122847.

Quach TT, Honnorat J, Kolattukudy PEK, Khanna R and Duchemin AM. CRMPs: critical molecules for neurite morphogenesis and neuropsychiatric diseases. Molecular Psychiatry 2015 Sep;20(9):1037-45. PMID: 26077693.

Shimomura A, Patel D, Wilson SM, Koehler KR, Khanna R, Hashino E. Tlx3 Promotes Glutamatergic Neuronal Subtype Specification through Direct Interactions with the Chromatin Modifier CBP. PLoS One. Aug 10;10(8):e0135060. eCollection 2015. PMID: 26258652.

Moutal A, Chew LA, Yang X, Wang Y, Yeon SK, Telemi E, Meroueh S, Park KD, Shrinivasan R, Gilbraith KB, Qu C, Xie JY, Patwardhan A, Vanderah TW, Khanna M, Porreca F, Khanna R#. (S)-Lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. Pain. 2016 Mar 9. PMID: 26967696.
Selected for cover image of issue

Quach TT, Honnorat J, Kolattukudy PE, Khanna R, Duchemin AM. Collapsin response mediator protein 3 increases the dendritic arborization of hippocampal neurons. Molecular Psychiatry 2015 Sep;20(9):1027. doi: 10.1038/mp.2015.123. PMID: 26293908.

Quach TT, Auvergnon N, Lerch J, Honnorat J, Khanna R, Kolattukudy PE and Duchemin AM. Cytoskeleton and CRMPs in Neuronal Morphogenesis and Neurological Diseases: Potential Targets for New Therapies. J Neurol Disord 2016, 4:1http://dx.doi.org/10.4172/2329-6895.1000257

Quach TT, Lerch J, Honnorat J, Khanna R, and Duchemin AM. Neuronal networks in mental diseases and neuropathic pain: Beyond BDNF and CRMPs. World J Psychiatr 2016 Mar 22;6(1):18-30. PMID: 27014595

Moutal A, Dustrude E.T., Khanna R#. Sensitization of ion channels contributes to central and peripheral dysfunction in Neurofibromatosis type 1. Molecular Neurobiology. (in press).

Patents: 
2006    Disclosure of invention: “Fractional recovery analysis of protein complexes” a method to derive the sequence of proteins in a solubilized multiprotein complex to the technology development and commercialization office, university health network, the University of Toronto, Toronto, Ontario, Canada.
2009    Disclosure of invention: “Transmission Regulatory Peptides (TRePs) that interfere with CRMP-2:Cav2.2 interactions: tools for studies of synaptic function and potential targets for synaptopathies” (10033) to the office of technology transfer, Indiana University.
2011    PCT/US11/40100 materials and methods for suppressing inflammation and neuropathic pain.
2012    UA provisional patent application us provisional patent application no. 61/588,831.  Compounds, composition, and methods for treating neuropathic pain.
2012    US provisional patent application 29920-220647: compounds and methods for the prophylactic treatment of epilepsy.
2012    Disclosure of invention: Neurological aryl unit (NAU): a structural entity or pharmacophore unit for the control of neuronal hyperexcitability disorders (filed by Rajesh Khanna, IUSM and Harold Kohn, University of North Carolina)
2012    Disclosure of invention: functional recovery following traumatic brain injury by sparing motoneuron dendrites from atrophy with a novel peptide therapeutic (12174 IURTC)
2012    Peptides conjugates for treating crmp2-calcium channel mediated pain, U.S. provisional patent application no. 61/655,380
2014    Disclosure of invention: CRMP2 SUMOylation motif (CSM) peptide: a novel non-narcotic peptide affecting sodium channel trafficking for chronic pain (Rajesh Khanna and co-inventors May Khanna, Todd w. Vanderah, and Erik T. Dustrude) UA-100; US provisional patent application no. 61/949,456
2015    US provisional patent application us provisional patent application no. 62/238,182.  SUMOylation inhibitors of Nav1.7 and their uses
2016    Disclosure of invention: inhibitors of voltage-gated calcium channel alpha-beta interactions: novel anti-allodynic compounds (Rajesh Khanna, Vijay Gokhale, and May Khanna) UA16-139
2016    Disclosure of invention: Small molecule allosteric antagonists of Cav2.2 calcium channels and uses thereof (Rajesh Khanna and Vijay Gokhale) UA16-145/US provisional patent application No. 62/314,055
2016    Disclosure of invention: Using light to create an animal migraine and pain model (Mohab M. Ibrahim and Rajesh)
Sponsored Research Through MSRP: 
Alexander Urzua (MSRP 2017): "Determining Gender and Stimulus Specific Differences in a Novel CRISPR/Cas9 Rat Model of Neurofibromatosis 1 (NF1)"
 
NIH Undergraduate Diversity Program: 
Ahmed Al-Shamari, 2016; "Endoplasmic Reticulum Stress an Migraine?"
 
Angie Dorame, 2016; "Calcium Channel Alterations in Rat Model of Migraine."
 
NIH High School Student Research Program: 
-Nicole Robles, Desert View High School, 2014
-Denise Salas Villa, Tucson High Magnet School, 2014, 2015
-Nicholas Boria, Paradise Valley High School, 2016
 

 

Tuesday, August 29, 2017